A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa

PHASE2CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

January 8, 2007

Primary Completion Date

May 26, 2009

Study Completion Date

May 26, 2009

Conditions
Retinitis Pigmentosa
Interventions
COMBINATION_PRODUCT

Low Dose NT-501

Low Dose NT-501 Implanted in study eye and fellow eye received sham surgery

COMBINATION_PRODUCT

High Dose NT-501

High Dose NT-501 Implanted in study eye and fellow eye received sham surgery

Trial Locations (11)

10016

NY University Medical Center, New York

38163

The Hamilton Eye Institute, Memphis

48105

Kellogg Eye Center, Ann Arbor

75231

Retina Foundation of Southwest, Dallas

90211

Retina-Vitreous Associates Medical Group, Beverly Hills

95817

University of Califoria, Davis, Sacramento

94143-0730

University of California, San Francisco, San Francisco

33021-6746

Retina Group of Florida, Hollywood

32216-1480

University of Florida, Jacksonville

55455-0501

University of Minnesota, Minneapolis

97239-4197

Casey Eye Institue, Portland

Sponsors
All Listed Sponsors
lead

Neurotech Pharmaceuticals

INDUSTRY